116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis.
Saved in:
| Title: | 116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis. |
|---|---|
| Authors: | El Zarif, T.1 (AUTHOR), Pond, G.2 (AUTHOR), Nassar, A.3 (AUTHOR), Adib, E.3 (AUTHOR), Freeman, D.1 (AUTHOR), Thomas, J.4 (AUTHOR), Kalluri, U.5 (AUTHOR), Matar, A.6 (AUTHOR), Kelly, E.7 (AUTHOR), Curran, C.1 (AUTHOR), Kadamkulam Syriac, A.8 (AUTHOR), McClure, H.1 (AUTHOR), Davidsohn, M.1 (AUTHOR), Labaki, C.1 (AUTHOR), Saliby, R.M.1 (AUTHOR), Hobeika, C.S.3 (AUTHOR), Nuzzo, P.V.1 (AUTHOR), Berchuck, J.E.9 (AUTHOR), Choueiri, T.K.10 (AUTHOR), Sonpavde, G.P.11 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS591-S592. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.148 |
